Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEADER 75: Gadovist vs Dotarem in CNS Imaging
NCT03602339Phase 4Completed
- Sponsor
- Bayer
- Start
- Nov 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, open-label trial of gadobutrol in Central nervous system lesion (2 arms), sponsored by Bayer. Primary endpoints: Degree of Lesion Contrast Enhancement up to 20 days, Lesion Border Delineation up to 20 days and 1 more. Started Nov 2018; status: completed.
02
Drugs
gadobutrol
03
Conditions
Central nervous system lesion
Beyond the preview
Go deeper on NCT03602339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03602339.